European Medicines Agency Validates Type II Variation for Astellas XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.